{
    "body": "Is dupilumab an antibody targeting the IL-1 receptor?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26440137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27130691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23688323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27497276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26308331"
    ], 
    "ideal_answer": [
        "No, Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways."
    ], 
    "exact_answer": "no", 
    "type": "yesno", 
    "id": "58df5efbc784871774000001", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 272, 
            "text": "Atopic dermatitis (AD) is characterized by type 2 helper T (Th2) cell-driven inflammation. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 625, 
            "offsetInEndSection": 818, 
            "text": "Dupilumab, a humanized monoclonal antibody to the interteukin-4R is the first antibody (i.e. 'biological') with published efficacy shown in controlled prospective studies in atopic dermatitis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308331", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 248, 
            "text": "Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1051, 
            "offsetInEndSection": 1337, 
            "text": "Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor \u03b1-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27497276", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 187, 
            "text": " Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1015, 
            "offsetInEndSection": 1169, 
            "text": "Dupilumab was also introduced as a possible treatment for patients with severe pemphigus. It can directly inhibit IL-4 by targeting IL-4 \u03b1-chain receptor.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440137", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 62, 
            "offsetInEndSection": 217, 
            "text": "We evaluated the efficacy and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the alpha subunit of the interleukin-4 receptor", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23688323", 
            "endSection": "abstract"
        }
    ]
}